2026-06-27T16:20:53Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/957752025-03-18T15:23:44Zcom_20.500.14352_14col_20.500.14352_15

Barrio, Manuel de Tornero Molina, Pilar Prieto, A. Sainza, T. Zubeldia Ortuño, José Manuel Herrero, T. 2024-01-29T09:21:23Z 2024-01-29T09:21:23Z 1997-05-01 de Barrio M, Tornero P, Prieto A, Sainza T, Zubeldia JM, Herrero T. Recurrent fixed drug eruption caused by citiolone. J Investig Allergol Clin Immunol. 1997 May-Jun;7(3):193-4. PMID: 9252880. 1018-9068 https://hdl.handle.net/20.500.14352/95775 1698-0808 9252880 https://pubmed.ncbi.nlm.nih.gov/9252880/ Citiolone (N-acetylhomocysteinethiolactone) is a thiolic­derived medication frequently used in Spain and in other countries as a mucolytic agent for the treatment of certain hepatic disorders. Mucolytic drugs have rarely been implicated in the fixed drug eruption etiology. We report on a patient who presented several episodes of fixed exanthema related to citiolone intake. The patch test with citiolone (10% in dimethyl sulfoxide) was negative. The diagnosis was confirmed by a positive controlled oral challenge test. Other mucolytic thiolic­derivatives (N-acetylcysteine) were tolerated by the patient, thus crossreactivity between these drugs seems to be unlikely. eng restricted access Recurrent fixed drug eruption caused by citiolone journal article